Position in GNLX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$28,451
-$84,377 QoQ
Shares Held
11,757
-54.6% QoQ
Ownership
0.026%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GNLX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026MAI Capital Management holds $16,740,876 across 273 Biotechnology names. GNLX ranks #50 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
6,357 | $4,911,672 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,218 | $990,425 | |
| 3 | DNLI |
Denali Therapeutics Inc.
|
46,590 | $894,528 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
3,932 | $785,023 | |
| 5 | TRVI |
Trevi Therapeutics, Inc.
|
65,125 | $776,941 | |
| 6 | IBRX |
ImmunityBio, Inc.
|
72,843 | $558,705 | |
| 7 | BCAB |
BioAtla, Inc.
|
51,504 | $414,607 | |
| 8 | RPRX |
Royalty Pharma plc
|
8,477 | $406,641 |
All Filings in GNLX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $28,451 | 11,757 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $112,828 | 25,878 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $134,370 | 31,993 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $678,907 | 236,553 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $963 | 357 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $672 | 285 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||